A first-in-class, biodegradable, intracameral implant for IOP control
24/7 drug delivery for several months1,2

scroll

DURYSTATM is directly delivered to target tissues in the anterior chamber angle1,3

Following administration, the intracameral implant is intended to settle within the inferior angle to deliver a sustained release of bimatoprost.1


Bimatoprost is believed to lower IOP in humans by increasing the outflow of aqueous humor through both the trabecular meshwork (conventional) and the uveoscleral routes (unconventional).1


Placement of the implant within the anterior chamber angle allows for close proximity to the tissues involved in both of these outflow pathways, where it delivers bimatoprost 24/7 for several months.1-3

anterior-chamber-angle-thumbnail
patient-thumbnail-2

Meet Diane 65 years old and an active school teacher

She may be an ideal candidate for DURYSTA

Her IOP is uncontrolled

Personal History

Has previously undergone SLT

Does not want to undergo incisional surgery

Due to other medical and personal priorities, she needs more time before taking the next step in her treatment

Considerations for Other Patients

Clinical

Patients who are unsuitable for topical drop therapy

Patients who have previously undergone SLT

Access

Medicare FFS with a supplemental insurance plan

FFS=fee-for-service; SLT=selective laser trabeculoplasty.

Considerations for Other Patients

Clinical

Patients who are
unsuitable for topical
drop therapy

Patients who have
previously undergone
SLT

Access

Medicare FFS with a
supplemental
insurance plan

FFS=fee-for-service;
SLT=selective laser
trabeculoplasty.

patient-picture patient-picture

Efficacy demonstrated in 2 clinical studies
Sustained IOP control, month after month1

Study Design

A safety profile established in 2 clinical studies1

MOST COMMON ADVERSE REACTIONS

ocular-icon Ocular

The most common ocular adverse reaction was conjunctival hyperemia, which occurred in 27% of patients.1

Other common ocular adverse reactions reported in 5-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, IOP increased, corneal endothelial cell loss, vision blurred, and iritis.1

Ocular adverse reactions occurring in 1-5% of patients were anterior chamber cell, lacrimation increased, corneal edema, aqueous humor leakage, iris adhesions, ocular discomfort, corneal touch, iris hyperpigmentation, anterior chamber flare, anterior chamber inflammation, and macular edema.1

non-ocular Nonocular

The most common nonocular adverse event was headache, which was observed in 5% of patients.1

You have options when ordering DURYSTA

FOR ORDERING

Choose to order online with Allergan Direct through the buy-and-bill process—or acquire DURYSTA through a specialty pharmacy. The videos below provide introductions to each of these options.

BnB-thumbnail-2

ORDERING DURYSTA ONLINE WITH ALLERGAN DIRECT

Allergan Direct offers a convenient experience with 24/7, on-demand flexibility. This solution allows you to place orders, pay invoices, and more.

contact-icon

Before ordering, you'll need to set up an Allergan Direct account by calling: 1-833-DURYSTA (1-833-387-9782)

Important

Call from 8 am to 8 pm ET

Have your practice contact information ready—including billing and shipping addresses—and your state license number

In order to run a credit check, we will need your business tax ID, bank name, account number, and contact information

If you already have an account for Allergan Direct, remember:

There is a minimum order quantity of 2

Orders arrive within 2 business days

New accounts receive an initial courtesy credit line of $20,000 while we process your credit application

Limited time, introductory purchasing offer
Following purchase, an invoice with a 180-day payment window will be sent with the order
BnB-thumbnail-2

HOW TO ORDER THROUGH A SPECIALTY PHARMACY

Start with Allergan EyeCue®

The benefits verification process will determine if your patient's insurance accommodates specialty pharmacy distribution

Allergan EyeCue® will then help coordinate the specialty pharmacy experience

The specialty pharmacy contacts the patient to verify information and collect their copay

Next, your office receives DURYSTA from the specialty pharmacy and properly stores it

Finally, you administer DURYSTA to the patient when needed

Sp-Pharmacy-thumbnail-1
Sp-Pharmacy-thumbnail-1

Reimbursement support with Allergan EyeCue®

FOR REIMBURSEMENT HELP

YOUR COMPLETE RESOURCE FOR DURYSTA REIMBURSEMENT AND ACCESS

allergan-eyecue-intro

For your DURYSTA patients, through Allergan EyeCue® you can:

Initiate a benefit verification

Request prior authorization support

Gain online access to case/patient management

Access information about billing, coding, and reimbursement support

Request specialty pharmacy enrollment

Request claims assistance and appeals support

Enroll commercially eligible patients in the DURYSTA Savings Program—which allows patients to pay as little as $20 per implant*

Submit claims for reimbursement under the DURYSTA Savings Program

Before you can begin taking advantage of this resource for ongoing DURYSTA support, an Allergan EyeCue® account is required. Details are available at the Allergan EyeCue® site.

Maximum savings limit of $1000 per eye applies; patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs). Other limitations may apply.

allergan-eyecue-intro

The DURYSTA Physician Training Portal

FOR ADMINISTRATION HELP

DESIGNED TO INTRODUCE YOU TO THE IMPLANT DELIVERY DIRECTIONS FOR DURYSTA

The Physician Training Portal provides:

An overview of the drug delivery system and mechanism of action

Demonstrations of correct administration technique

Examples of typical implant behavior following administration

A guide through various troubleshooting scenarios

For complete administration instructions, a downloadable administration guide is also available in the resources section of this site

Download materials and resources for your practice and your patients

For Your Practice

ORDERING

ordering-icon
How to Order Flashcard

A handy reference to consult when ordering DURYSTA

REIMBURSEMENT

reimbursement-icon
Allergan EyeCue® Patient Enrollment Form

Quickly enroll patients in Allergan EyeCue® to begin taking advantage of the available resources

ADMINISTRATION TRAINING

admin-training-icon
Physician's Administration Guide

A complete reference for the DURYSTA administration procedure


ADDITIONAL RESOURCES

For Your Patients

patient-brochure-icon
DURYSTA Patient Brochure

A helpful resource for introducing new patients to DURYSTA

patient-flash-card-icon
DURYSTA Savings Program Patient Flashcard

All the information eligible patients need to enroll and begin saving on their DURYSTA prescription costs

up-arrow-icon

INDICATIONS AND USAGE

DURYSTA (bimatoprost implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

IMPORTANT SAFETY INFORMATION

Contraindications

DURYSTA is contraindicated in patients with: active or suspected ocular or periocular infections; corneal endothelial cell dystrophy (e.g., Fuchs’ Dystrophy); prior corneal transplantation or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]); absent or ruptured posterior lens capsule, due to the risk of implant migration into the posterior segment; hypersensitivity to bimatoprost or to any other components of the product.

Warnings and Precautions

The presence of DURYSTA implants has been associated with corneal adverse reactions and increased risk of corneal endothelial cell loss. Administration of DURYSTA should be limited to a single implant per eye without retreatment. Caution should be used when prescribing DURYSTA in patients with limited corneal endothelial cell reserve.

DURYSTA should be used with caution in patients with narrow iridocorneal angles (Shaffer grade < 3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle.

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic bimatoprost, including DURYSTA intracameral implant. DURYSTA should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Prostaglandin analogs, including DURYSTA, have been reported to cause intraocular inflammation. DURYSTA should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

Ophthalmic bimatoprost, including DURYSTA intracameral implant, has been reported to cause changes to pigmented tissues, such as increased pigmentation of the iris. Pigmentation of the iris is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased pigmentation. While treatment with DURYSTA can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Intraocular surgical procedures and injections have been associated with endophthalmitis. Proper aseptic technique must always be used with administering DURYSTA, and patients should be monitored following the administration.

Adverse Reactions

In controlled studies, the most common ocular adverse reaction reported by 27% of patients was conjunctival hyperemia. Other common adverse reactions reported in 5%-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure increased, corneal endothelial cell loss, vision blurred, iritis, and headache.

Please see full Prescribing Information.

References: 1. DURYSTA [Prescribing Information]. Irvine, CA: Allergan, Inc.; 2020. 2. Data on file, Allergan, 2020. 3. Standring S. Orbit and accessory visual apparatus. In: Gray’s Anatomy: The Anatomical Basis of Clinical Practice. 41st ed. Philadelphia, PA: Elsevier Limited; 2016: 666-708. 4. DURYSTA NDA FDA Approval Letter. March 4, 2020.

IMPORTANT SAFETY INFORMATION AND INDICATIONS AND USAGE
COLLAPSE

Contraindications

DURYSTA is contraindicated in patients with: active or suspected ocular or periocular infections; corneal endothelial cell dystrophy (e.g., Fuchs’ Dystrophy); prior corneal transplantation or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]); absent or ruptured posterior lens capsule, due to the risk of implant migration into the posterior segment; hypersensitivity to bimatoprost or to any other components of the product.

Warnings and Precautions

The presence of DURYSTA implants has been associated with corneal adverse reactions and increased risk of corneal endothelial cell loss. Administration of DURYSTA should be limited to a single implant per eye without retreatment. Caution should be used when prescribing DURYSTA in patients with limited corneal endothelial cell reserve.

DURYSTA should be used with caution in patients with narrow iridocorneal angles (Shaffer grade < 3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle.

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic bimatoprost, including DURYSTA intracameral implant. DURYSTA should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Prostaglandin analogs, including DURYSTA, have been reported to cause intraocular inflammation. DURYSTA should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

Ophthalmic bimatoprost, including DURYSTA intracameral implant, has been reported to cause changes to pigmented tissues, such as increased pigmentation of the iris. Pigmentation of the iris is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased pigmentation. While treatment with DURYSTA can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Intraocular surgical procedures and injections have been associated with endophthalmitis. Proper aseptic technique must always be used with administering DURYSTA, and patients should be monitored following the administration.

Adverse Reactions

In controlled studies, the most common ocular adverse reaction reported by 27% of patients was conjunctival hyperemia. Other common adverse reactions reported in 5%-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure increased, corneal endothelial cell loss, vision blurred, iritis, and headache.

INDICATIONS AND USAGE

DURYSTA (bimatoprost implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

Please see full Prescribing Information.

close
desktop-jcode mobile-jcode
desktop-jcode1 mobile-jcode1
PROCEED

*Effective for dates of service on or after October 1, 2020, bill as 10 units.

© 2020 Allergan. All rights reserved. All trademarks are
the property of their respective owners. DUR139462 08/20